Best Drug Development Company

RNS Number : 8786J

Immupharma PLC

08 April 2010

 



For Immediate Release

8 April 2010

ImmuPharma PLC

("ImmuPharma")

ImmuPharma awarded Best Drug Development Company in Europe Award

ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company, has been voted "Best Drug Development Company, Europe" at The New Economy Pharmaceutical & Healthcare Awards 2010.

This award follows on from two notable wins in 2009 namely; "Best Technology Award" at the AIM Awards, organized by the London Stock Exchange and "Breakthrough of the year 2009" at the European Mediscience Awards.

- Ends -

For further information please contact:

ImmuPharma PLC	[phone]
Dimitri Dimitriou, Chief Executive Officer Richard Warr, Chairman
Buchanan Communications	[phone]
Lisa Baderoon George Prassas
Panmure Gordon & Co                                                            Andrew Burnett Rakesh Sharma	[phone]
Noble & Company Limited	[phone]
James Bromhead

Notes to Editors:

About ImmuPharma PLC

ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders.

Its lead candidate for the treatment of Lupus, Lupuzor^TM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties.  $45m in cash has been received to date.

The company also has a strong proprietary and collaborative drug development pipeline.

 

END

 

 

MSCEAPLPEALEEEF